Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • Medicines in Devlopment for Cancer, 2008  
  • Since 1975, the five year survival rate for breast cancer patients has increased by 40 percent.  
  • Since 1980, 83 percent of gains in life expectancy for cancer patients have been attributable to new treatments.